These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 25828651)

  • 21. Epirubicin extravasation: consequences of delayed management.
    Hale O; Deutsch PG; Lahiri A
    BMJ Case Rep; 2017 Jan; 2017():. PubMed ID: 28062432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Results of clinical study with epirubicin hydrochloride injectable solution for superficial bladder cancer. IMI28 Injectable Solution Study Group for Superficial Bladder Cancer].
    Kotake T; Koyanagi T; Akaza H; Shimazaki J; Ito H; Hosaka M; Okajima E; Saito Y; Miyanaga N; Kuroda M; Hirao Y
    Gan To Kagaku Ryoho; 1998 Jul; 25(8):1189-95. PubMed ID: 9679582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity.
    Prado CM; Lima IS; Baracos VE; Bies RR; McCargar LJ; Reiman T; Mackey JR; Kuzma M; Damaraju VL; Sawyer MB
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):93-101. PubMed ID: 20204364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of venous pain and phlebitis caused by epirubicin hydrochloride.
    Sugimoto M; Matsui M; Harada M; Yamauchi Y; Moriyama N; Andou K; Yamamoto M; Yamaoka H; Ono C; Ishikawa M; Kamo N; Ikeda T; Yamaoka K
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):969-74. PubMed ID: 19542717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
    Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
    J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An increase of serum lipids after cumulative doses of doxorubicin and epirubicin in experimental animals.
    Stathopoulos GP; Papadopoulos NG; Stephanopoulou A; Dontas I; Kotsarelis D; Karayannacos PE
    Anticancer Res; 1996; 16(6B):3429-33. PubMed ID: 9042202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epirubicin-induced Kounis syndrome.
    Liang HZ; Zhao H; Gao J; Cao CF; Wang WM
    BMC Cardiovasc Disord; 2021 Mar; 21(1):133. PubMed ID: 33711934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of infusion regime on doxorubicin pharmacokinetics in the cat.
    Hahn KA; Frazier DL; Cox SK; Legendre AM
    J Am Anim Hosp Assoc; 1997; 33(5):427-33. PubMed ID: 9278119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization.
    Tanaka T; Ikeda M; Okusaka T; Ueno H; Morizane C; Ogura T; Hagihara A; Iwasa S
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):683-8. PubMed ID: 17541589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversible Cardiomyopathy After Epirubicin Administration.
    Koitabashi N; Ohyama Y; Tateno R; Arai M; Rokutanda N; Horiguchi J; Kurabayashi M
    Int Heart J; 2015; 56(4):466-8. PubMed ID: 26104177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors.
    Lübbe AS; Bergemann C; Riess H; Schriever F; Reichardt P; Possinger K; Matthias M; Dörken B; Herrmann F; Gürtler R; Hohenberger P; Haas N; Sohr R; Sander B; Lemke AJ; Ohlendorf D; Huhnt W; Huhn D
    Cancer Res; 1996 Oct; 56(20):4686-93. PubMed ID: 8840985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Arterial infusion of SMANCS for multiple recurrent tumors after hepatic resection].
    Takano S; Kono S; Iwai S
    Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():34-8. PubMed ID: 9512685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Case of epirubicin-induced cardiomyopathy in familial cardiomyopathy.
    Shipman KE; Arnold I
    J Clin Oncol; 2011 Jun; 29(18):e537-8. PubMed ID: 21482996
    [No Abstract]   [Full Text] [Related]  

  • 34. Tropisetron in the prevention of acute nausea and vomiting in patients treated with high dose epirubicin.
    Nicolaides C; Giannakakis T; Skarlos D; Athanassiadis A; Fountzilas G; Damigos D; Pavlidis N
    J Exp Clin Cancer Res; 1998 Mar; 17(1):71-5. PubMed ID: 9646236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
    Catimel G; Spielmann M; Dieras V; Kayitalire L; Pouillart P; Guastalla JP; Soler-Michel P; Graffand N; Garet F; Dumortier A; Pellae-Cosset B; Chazard M
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):24-7. PubMed ID: 8629032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pilot study of multiple chemotherapy resistance modulators plus epirubicin in the treatment of resistant malignancies.
    Stewart DJ; Cripps MC; Goel R; Dahrouge S; Yau J; Tomiak E; Huan S; Soltys K; Prosser A; Davies RA
    Cancer Chemother Pharmacol; 1997; 41(1):1-8. PubMed ID: 9443607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of transcatheter arterial embolization and percutaneous ethanol injection for hepatocellular carcinoma: comparison of efficacies of doxorubicin and epirubicin in transcatheter arterial embolization.
    Nakamura S; Tanaka K
    Semin Oncol; 1997 Apr; 24(2 Suppl 6):S6-46-S6-49. PubMed ID: 9151916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatic uptake of epirubicin by isolated rat hepatocytes and its biliary excretion after intravenous infusion in rats.
    Shin DH; Park SH; Jeong SW; Park CW; Han K; Chung YB
    Arch Pharm Res; 2014 Dec; 37(12):1599-606. PubMed ID: 25373308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epirubicin seems to cause venous sclerosis.
    Lennan E; Middleton JM; Luken J
    BMJ; 2005 Oct; 331(7522):966. PubMed ID: 16239707
    [No Abstract]   [Full Text] [Related]  

  • 40. Re: Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906).
    Mehraban D; Esfahani F
    J Urol; 2005 Sep; 174(3):1151; author reply 1151. PubMed ID: 16094088
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.